FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/01/079482 [Registered on: 27/01/2025] Trial Registered Prospectively
Last Modified On: 25/01/2025
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Using Mudgaparni medicated Go ghrita Eye Drops to Manage Computer Vision Syndrome 
Scientific Title of Study   A Randomized Controlled Clinical Study on Effect of Mudgaparni Siddha Goghrita Aschyotana in Computer Vision Syndrome 
Trial Acronym  NIL 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Sandeep Rawat 
Designation  PG Scholar 
Affiliation  Bharati Vidyapeeth(Deemed to be University) 
Address  Bharati Vidyapeeth(Deemed to be University), College of Ayurved & Hospital,Dhankawadi ,Pune Department of Shalakya Tantra Room number 24

Pune
MAHARASHTRA
411043
India 
Phone  8511538809  
Fax    
Email  sandeep.rawat-ayurved@bvp.edu.in  
 
Details of Contact Person
Scientific Query
 
Name  Dr Santosh Mulik 
Designation  Head of Department  
Affiliation  Bharati Vidyapeeth (Deemed to be University), College of Ayurved, Pune-43 
Address  Bharati Vidyapeeth (Deemed to be University), College of Ayurved, Pune-43

Pune
MAHARASHTRA
411043
India 
Phone  9823491389  
Fax    
Email  mulik.santosh@bharatividyapeeth.edu  
 
Details of Contact Person
Public Query
 
Name  Dr Santosh Mulik 
Designation  Head of Department  
Affiliation  Bharati Vidyapeeth (Deemed to be University), College of Ayurved, Pune-43 
Address  Bharati Vidyapeeth (Deemed to be University), College of Ayurved, Pune-43 Department of Shalakya Tantra Room number 24

Pune
MAHARASHTRA
411043
India 
Phone  9823491389  
Fax    
Email  mulik.santosh@bharatividyapeeth.edu  
 
Source of Monetary or Material Support  
Bharati Ayurved Hospital, Bharati Vidyapeeth Campus, Dhankawadi, Pune, Maharashtra, India 411043  
 
Primary Sponsor  
Name  Dr Sandeep Rawat 
Address  Bharati Vidyapeeth(Deemed to be University), College of Ayurved & Hospital, Department of Shalakyatantra,OPD No.-24 Katraj, Dhankawadi , Pune 
Type of Sponsor  Other [Self] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Sandeep Rawat  Bharati Ayurved Hospital   Bharati Vidyapeeth (Deemed to be University), College of Ayurved and Hospital, Department of Shalakya Tantra, room number 24, Katraj, Dhankawadi, Pune 411043
Pune
MAHARASHTRA 
8511538809

sandeep.rawat-ayurved@bvp.edu.in 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
ETHICS COMMITTEE [BV(DU)COA-EC]  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:H049||Disorder of lacrimal system, unspecified. Ayurveda Condition: SUSHKAKSHIPAKAH,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Comparator Arm (Non Ayurveda)-Carboxymethyl cellulose 0.5% eye dropsInstillation of 2 drops, 3 times a day, both eyes for 30 days
2Intervention ArmDrugClassical(1) Medicine Name: Mudgaparni Siddha Goghrita, Reference: Ashtang Hridya, Route: Topical, Dosage Form: Ghrita, Dose: 2(drops), Frequency: bd, Bhaishajya Kal: Abhakta, Duration: 30 Days, anupAna/sahapAna: No, Additional Information: -
 
Inclusion Criteria  
Age From  15.00 Year(s)
Age To  45.00 Year(s)
Gender  Both 
Details  1 Patients suffering from Computer Vision Syndrome will be selected
2 Patients will be selected irrespective of gender, socio-economic status and religion.
 
 
ExclusionCriteria 
Details  1 Any ocular surface pathology.
2 Any ocular disease other than Computer Vision syndrome
3 Patient aged below 15 and above 45 years
4 Congenital anomalies of eye.
5 One eyed patient 
 
Method of Generating Random Sequence   Other 
Method of Concealment   Case Record Numbers 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Dryness of eye will be assessed
Eye fatigue will be assessed  
Dryness and eye fatigue will be assessed on 7th day, 15th day and on 30th day 
 
Secondary Outcome  
Outcome  TimePoints 
Eye redness will be assessed
Burning sensation will be assessed
Itching sensation will be assessed
Headache will be assessed  
Eye redness, burning sensation, itching sensation & headache will be assessed also after 3 months  
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 2/ Phase 3 
Date of First Enrollment (India)   10/02/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  
This study is a randomised, controlled, open label, parallel group study on effect of
Mudgaparni Siddha Goghrita Aschyotana in Computer Vision Syndrome for 30 days in 30 patients with Computer vision syndrome that will be conducted in Bharati Vidyapeeth (Deemed to be University), College of Ayurved and Hospital, Department of Shalakya Tantra, OPD number 24, Katraj, Dhankawadi, Pune
411043. 
The primary outcome measures will be reduction in the Dryness of eye and Eye fatigue. The secondary outcomes will be Reduction in symptoms of Eye redness, Burning
sensation, Itching sensation and Headache.
 
Close